FOR LABORATORY RESEARCH PURPOSES ONLY. This compound has not received FDA approval. All information shown is drawn from published laboratory research for educational purposes
$50.00
Lost, stolen, or damaged? We replace it, on us.
Pick your speed at checkout.
Before you continue
This site sells research products exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
Selank is a synthetic peptide analogue of tuftsin, a naturally occurring peptide, supplied by Peppy Peptides for laboratory research use only. It is a well-characterized compound for controlled studies of neurochemical and immune signaling.
Selank is based on tuftsin, a short, naturally occurring peptide fragment, extended with an additional tripeptide sequence for greater stability in research settings. It belongs to the broader class of regulatory peptides that researchers examine for their interaction with neurochemical signaling systems.
Laboratory research on Selank has focused on stress-response pathways and neurotransmitter-signaling systems, including its relationship to GABAergic and monoaminergic activity in cell and animal models.
Selank is referenced in laboratory literature on stress-response physiology, where researchers study its interaction with neuroendocrine signaling pathways in cell-based and animal-model systems. It is also examined in in vitro models of GABAergic and serotonergic signaling.
Because Selank is structurally related to tuftsin, published research has also examined its interaction with immune-signaling pathways. Its extended tripeptide sequence distinguishes it from native tuftsin, so researchers studying peptide stability and blood-brain-barrier permeability have used Selank as a reference compound in structure-activity studies and laboratory pharmacokinetic modeling.
Selank is studied for its interaction with stress-response and neurotransmitter-signaling pathways, including GABAergic and monoaminergic systems, in cell and animal models.
Selank extends the tuftsin sequence with an additional tripeptide. Researchers use this structural difference in stability and structure-activity studies that compare Selank with the native peptide.
Published laboratory research on Selank is indexed on PubMed.
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. This compound has not received FDA approval. All information shown is drawn from clinical studies for educational purposes.
Researcher favourites
Price range: $125.00 through $175.00
Price range: $150.00 through $650.00
Price range: $125.00 through $700.00
$150.00
$175.00
Lab-verified quality
Each lot is analysed by Bioviridian before release. Below is the Certificate of Analysis for the most recent lot, as issued by the laboratory.
Overall purity
99.6%
RP-HPLC (214 nm)
View the signed COA (PDF)Check this certificate at bioviridians.com/coa-search.html with code COA7697.
Test results
5 of 5 conformHPLC retention time 2.287 min · Signed: Shane Straight, M.S., Principal Chemist, Bioviridian Inc.
Every lot keeps its own signed certificate. Lots are listed newest first.
Lot SEL072026-MG
99.6%
Overall purity
Tested July 13, 2026
Open COAEarlier lots will appear here as new Certificates of Analysis are published.
Compound details
Molecular profile
Storage requirements
Supplied lyophilized; store at −20°C for long-term stability; avoid repeated freeze-thaw cycles; protect from light
Refrigerate at 2–8°C after reconstitution; use within 4–6 weeks
Published literature
2 peer-reviewed publications indexed on PubMed. Listed for reference only; inclusion does not imply any use, effect or endorsement.
FRONT PHARMACOL · 2016
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, Shadrina M, Kolomin T, et al. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031
Measured expression of genes involved in GABAergic neurotransmission in rat frontal cortex after Selank administration.
FRONT PHARMACOL · 2017
Filatova E, Kasian A, Kolomin T, et al. Front Pharmacol. 2017;8:89. doi:10.3389/fphar.2017.00089
Compared the effects of GABA, Selank and olanzapine on expression of GABAergic-neurotransmission genes in the IMR-32 neuroblastoma cell line.
